Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.
| Identifer | oai:union.ndltd.org:ETSU/oai:dc.etsu.edu:etsu-works-3451 |
| Date | 01 March 2012 |
| Creators | Angles, M., Bossaer, John B. |
| Publisher | Digital Commons @ East Tennessee State University |
| Source Sets | East Tennessee State University |
| Detected Language | English |
| Type | text |
| Source | ETSU Faculty Works |
Page generated in 0.0498 seconds